Ironwood Pharmaceuticals Inc

NASDAQ:IRWDUnited States

Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. It is advancing apraglutide, a long-acting synthetic glucagon-like peptide-2 (GLP-2) analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. It is advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS), and endometriosis. It is also developing CNP-104 for the treatment of PBC, a rare autoimmune disease targeting the liver.

Contact Information

Headquarters

100 Summer Street, Suite 2300BOSTON, MA, United States 02110

Phone

617-621-7722

Fax

617-494-0480

Executives

Independent Chairman of the Board

Julie Mchugh

President, Interim Chief Executive Officer

Thomas Mccourt

Senior Vice President, Chief Financial Officer

Sravan Emany

Senior Vice President, Chief Legal Officer, Secretary

John Minardo

Senior Vice President, Chief Business Officer

Andrew Davis